Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ddACTHP vs TCHP in Early HER2+ Breast Cancer
NCT03329378Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2019
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Targeted Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, cyclophosphamide, Paclitaxel Micelles for Injection, trastuzumab, pertuzumab in HER2-positive breast cancer, sponsored by Icahn School of Medicine at Mount Sinai. Started Jan 2019; status: terminated.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injectiontrastuzumabpertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03329378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329378.